Is Aarti Pharmalabs a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Aarti Pharmalabs Ltd is a average quality company .

Is Aarti Pharmalabs undervalued or overvalued?

The key valuation ratios of Aarti Pharmalabs Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone .

What is Aarti Pharmalabs share price return in the past 10 years?

Data is not available for this company

Is Aarti Pharmalabs a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Aarti Pharmalabs Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

Aarti Pharmalabs Ltd - Stock Valuation and Financial Performance

Name: Aarti Pharmalabs
Brand: Aarti Pharmalabs

BSE: 543748 | NSE: AARTIPHARM | Pharmaceuticals & Drugs | Small Cap

Place order

Aarti Pharmalabs Share Price

₹617.80 -16.75 -2.64%
as on 21-Nov'24 16:59

10 Year X-Ray of Aarti Pharmalabs:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
ROCE % ⓘ	0%	0%	0%	0%	0%	-8.1%	-1.9%	18%	15.6%	16.6%	-
Value Creation Index ⓘ	NA	NA	NA	NA	NA	-1.6	-1.1	0.3	0.1	0.2	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	0	0	0	0	0	0	0	941	1,511	1,502	1,559
Sales YoY Gr.	-	NA	NA	NA	NA	NA	NA	NA	60.6%	-0.6%	-
Adj EPS ⓘ	0	0	0	0	0	-0.8	-0.2	4,268.2	19	22.1	22.8
YoY Gr.	-	NA	NA	NA	NA	NA	NA	NA	-99.6%	16.6%	-
BVPS (₹) ⓘ	0	0	0	0	0	9.3	9.1	49,558.5	158.7	178.9	188.4
Adj Net Profit ⓘ	0	0	0	0	0	0	0	107	172	200	206
Cash Flow from Ops. ⓘ	0	0	0	0	0	0	0	-64.8	216	184	-
Debt/CF from Ops. ⓘ	0	0	0	0	0	0	0	-5	1	1.4	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	NA	NA	NA	-0.6%
Adj EPS ⓘ	NA	NA	NA	16.6%
BVPSⓘ	NA	NA	169.7%	12.7%
Share Price	-	-	-	55.4%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
Return on Equity % ⓘ	-8.1	-2	16.6	12.6	13.1	12.4
Op. Profit Mgn % ⓘ	0	0	19.1	20.4	23	23.4
Net Profit Mgn % ⓘ	0	0	11.3	11.4	13.3	13.2
Debt to Equity ⓘ	0	0.1	0.3	0.1	0.2	0.1
Working Cap Days ⓘ	0	0	163	219	256	132
Cash Conv. Cycle ⓘ	0	0	116	150	166	67

Recent Performance Summary

No data to display

Return on Equity has declined versus last 3 years average to 12.40%

Sales growth has been subdued in last 3 years 0.00%

Net Profit has been subdued in last 3 years 0.00%

Sales growth is not so good in last 4 quarters at 7.61%

Latest Financials - Aarti Pharmalabs Ltd.

	Standalone	Consolidated
TTM EPS (₹)	22.8	25.2
TTM Sales (₹ Cr.)	1,559	1,968
BVPS (₹.) ⓘ	188.4	204.9
Reserves (₹ Cr.) ⓘ	1,662	1,811
P/BV ⓘ	3.37	3.10
PE ⓘ	27.89	25.21

From the Market
52 Week Low / High (₹)	380.65 / 721.00
All Time Low / High (₹)	269.00 / 721.00
Market Cap (₹ Cr.)	5,751
Equity (₹ Cr.)	45.3
Face Value (₹)	5
Industry PE ⓘ	43

Management X-Ray of Aarti Pharmalabs:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Aarti Pharmalabs

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Aarti Pharmalabs

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Sales	0	0	941	1,511	1,502
Operating Expenses ⓘ	0	0	761	1,203	1,156
Manufacturing Costs	0	0	202	170	183
Material Costs	0	0	452	818	752
Employee Cost	0	0	80	114	120
Other Costs ⓘ	0	0	27	101	101
Operating Profit ⓘ	0	0	180	308	346
Operating Profit Margin (%)	-	-	19.1%	20.4%	23.0%
Other Income ⓘ	0	0	3	1	11
Interest ⓘ	0	0	11	20	17
Depreciation ⓘ	0	0	37	56	66
Exceptional Items ⓘ	0	0	0	0	0
Profit Before Tax ⓘ	0	0	134	233	275
Tax ⓘ	0	0	27	62	74
Profit After Tax	0	0	107	172	201
PAT Margin (%)	-	-	11.3%	11.4%	13.4%
Adjusted EPS (₹)	-0.8	-0.2	4,269.1	19.0	22.1
Dividend Payout Ratio (%)	0%	0%	0%	11%	14%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Equity and Liabilities
Shareholders Fund	0	0	1,239	1,439	1,621
Share Capital ⓘ	0	0	0	45	45
Reserves ⓘ	0	0	1,239	1,393	1,576
Minority Interest	0	0	0	0	0
Debt	0	0	325	207	251
Long Term Debt	0	0	0	0	0
Short Term Debt	0	0	325	207	251
Trade Payables	0	0	132	212	255
Others Liabilities ⓘ	0	0	132	119	170
Total Liabilities ⓘ	0	0	1,827	1,976	2,297
Fixed Assets
Gross Block	0	0	1,101	1,304	1,472
Accumulated Depreciation	0	0	400	455	519
Net Fixed Assetsⓘ	0	0	701	848	953
CWIP ⓘ	0	0	187	102	137
Investmentsⓘ	0	0	40	55	62
Inventories	0	0	444	538	582
Trade Receivables	0	0	304	372	449
Cash Equivalents	0	0	56	0	4
Others Assetsⓘ	0	0	93	61	110
Total Assets ⓘ	0	0	1,827	1,976	2,297

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'22	Mar'23	Mar'24
Cash Flow From Operating Activity ⓘ	-65	216	184
PBT ⓘ	134	233	275
Adjustment ⓘ	46	77	81
Changes in Working Capital ⓘ	-230	-38	-125
Tax Paid ⓘ	-15	-57	-47
Cash Flow From Investing Activity ⓘ	-134	-116	-184
Capex	-136	-99	-146
Net Investments	0	-18	-48
Others ⓘ	2	1	10
Cash Flow From Financing Activityⓘ	255	-157	4
Net Proceeds from Shares ⓘ	0	0	0
Net Proceeds from Borrowing ⓘ	0	0	0
Interest Paid ⓘ	-11	-20	-17
Dividend Paid ⓘ	0	-18	-18
Others ⓘ	266	-118	39
Net Cash Flow ⓘ	56	-56	4

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Ratios
ROE (%)	N/A	N/A	17.23	12.83	13.11
ROCE (%)	N/A	N/A	18.03	15.6	16.55
Asset Turnover Ratio	0	0	1.03	0.79	0.7
PAT to CFO Conversion(x)	N/A	N/A	-0.61	1.26	0.92
Working Capital Days
Receivable Days	0	0	118	82	100
Inventory Days	0	0	172	119	136
Payable Days	0	0	53	77	113

Aarti Pharmalabs Ltd Stock News

Aarti Pharmalabs Ltd FAQs

What is the share price of Aarti Pharmalabs?

Company share prices are keep on changing according to the market conditions. The closing price of Aarti Pharmalabs on 21-Nov-2024 16:59 is ₹617.8.

What is the market cap of Aarti Pharmalabs?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 21-Nov-2024 16:59 the market cap of Aarti Pharmalabs stood at ₹5,750.7.

What is the P/E ratio of Aarti Pharmalabs?

The latest P/E ratio of Aarti Pharmalabs as of 21-Nov-2024 16:59 is 27.89.

What is the P/B ratio of Aarti Pharmalabs?

The latest P/B ratio of Aarti Pharmalabs as of 21-Nov-2024 16:59 is 3.37.

What is the 52-week high and low of Aarti Pharmalabs?

The 52-week high of Aarti Pharmalabs is ₹721.0 and the 52-week low is ₹380.6.

What is the TTM revenue of Aarti Pharmalabs?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Aarti Pharmalabs is ₹1,559 ( Cr.) .

About Aarti Pharmalabs Ltd

Aarti Pharmalabs Limited (APL) (Formerly known as Aarti Organics Limited) is a leading Indian manufacturer of Pharmaceuticals and Nutraceuticals with a global footprint.

Over the past two decades, enabled by cutting-edge R&D and manufacturing capabilities APL has evolved as a reliable partner of choice for generic players and innovators across the globe. The company specialises in generic APIs, generic intermediates, and xanthine derivatives. It delivers CDMO services for drug substance/NCE development and manufacturing for innovative pharmaceutical and biotech firms with a focus on the Ph-I/II/III, launch, and commercial phases. It has dedicated facilities for the production of HPAPIs, corticosteroids, cytotoxic medicines, and oncology products.

With the biggest manufacturing capacity in India for its flagship product ‘Caffeine’ APL has emerged as a preferred partner for the Beverages, Nutraceuticals manufacturing companies, and Pharmaceuticals Industries across the world.

Business area of the company

The company is an, internationally recognised manufacturer of Active Pharmaceutical Ingredients (API), pharmaceutical intermediates, New Chemical Entities (NCE), and xanthine derivatives situated in India. In order to build a sustainable future, it integrates process chemistry proficiency (recipe focus) with scale-up engineering proficiency (asset utilisation).

Products and services